Acta Med. 2000, 43: 125-128
https://doi.org/10.14712/18059694.2019.125
Effect of Acetyl-L-Carnitine on Leukemia L1210 Resistant to Mitoxantrone
References
1. T, Michelli R, Ricciolini M et al. Effect of acetyl-Lcarnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy. Brain Res 1989; 526:108.
<https://doi.org/10.1016/0006-8993(90)90255-A>
2. NR, Yu F. Johnson R. et al. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 1992; 41:993-8.
3. WT, Danks MK, Wolverton JS et al. Resistance of mammalian tumour cells to inhibitors of DNA topoisomerase II. Adv Pharmacol 1994; 29B:145-69.
<https://doi.org/10.1016/S1054-3589(08)61136-9>
4. MD m, Battelli DM, Guarriero U et al. Changes in mitochondrial activity caused by ammonium salts and the protective effect of carnitine. Biochim Biophys Res Commun 1989; 158:181.
<https://doi.org/10.1016/S0006-291X(89)80195-0>
5. RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995; 22(Suppl.1):11-3.
6. WR, Bernasconi C, Hutshinton RM, Windfield DA, De Bock R, Mandelli F. Mitoxantrone for refractory and relapsed acute leukemia. Cancer 1990; 96:418-22.
<https://doi.org/10.1002/1097-0142(19900801)66:3<418::AID-CNCR2820660303>3.0.CO;2-K>
7. WH Jr, Wampler GL, Stablein DM, Campbell ED. Drug activity and therapeutic synergism in cancer treatment. Cancer Res 1982; 42:2963-71.
8. De Jager R, Capeleare P, Earl H et al. Phase II clinical trial of mitoxantrone on solid tumours and lymphomas. Trial NCI/EORTC. Symposium on New Drugs on Cancer Therapy. Brussels, Belgium: Institut Jules Bordet, 1998:Abst 39.
9. G, De Simone C, Famularo G, Fegiz A, Paoletti F, Jirilio E. Anaesthetics modulate tumour necrosis factor (: effect of L-carnitine supplementation in surgical patients. Preliminary results. Mediat Inflam 1993; 2:33-6.
<https://doi.org/10.1155/S0962935193000730>
<PubMed>
10. JA, Ling V. The biochemistry of p-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989; 58:137-71.
<https://doi.org/10.1146/annurev.bi.58.070189.001033>
11. A, Bisseli R, Casciaro A, Tzantzoglou S, De Simone C. Regulation of normal human polymorphonuclear leukocytes by carnitine. Mediat Inflam 1993; 2:37-41.
<https://doi.org/10.1155/S0962935193000742>
<PubMed>
12. IB. Carnitine and its role on fatty acid metabolism. Adv Lipid Res 1963; 1:285-324.
<https://doi.org/10.1016/B978-1-4831-9937-5.50014-4>
13. A, Corbucci GG, De Blasi RA. Influence of acetyl-L-carnitine infusion on haemodynamic parameters and survival of circulatory - shock patients. Int J Clin Pharm Res XI 1991; 2:83-92.
14. J. Mechanisms of tumour cell resistance to cancer chemotherapeutic drugs. Eur J Surg 1991; (Suppl 561):35-44.
15. RH. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta (BBA)/Gene Struct Expres 1998; 1400:173-84.
16. KA, Norton JA. Cancer cachexia. J Parent Ent Nutr 1988; 12:286-92.
<https://doi.org/10.1177/0148607188012003286>
17. Koloničný A. Synthesis of Mitoxantrone (Ph.D.Thesis). Pardubice, Czech Republic: Technical University of Chemical Technology, 1990.
18. G. Adriamycin-dependent release of iron from microsomal membranes. Arch Biochem Biophys 1989; 268:398-403.
<https://doi.org/10.1016/0003-9861(89)90601-2>
19. CE, McGuire WP. Liss RH. et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumour response. Science 1977; 197:165-9.
<https://doi.org/10.1126/science.877547>
20. D, Skovsgaard T. P-glycoprotein as multidrug transporters; a critical review of current multidrug resistant cell lines. Biochim Biophys Acta 1992; 1139:169-83.
<https://doi.org/10.1016/0925-4439(92)90131-6>
21. PA, Ohmuma T, Ambinder E. Effects of mitoxantrone on patients with refractory acute leukemia. Blood 1981; (Suppl 58):145.
22. EW, Long CL, Nielson KM et al. Glucose metabolism in advanced lung cancer patients. Nutrition 1992; 8:245-51.
23. V, D’Vrso M, Albertoni C, Campo S, Foresta P, Martelli EA. LPS - induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives. Mediat Inflam 1993; 2:43-50.
<https://doi.org/10.1155/S0962935193000754>
<PubMed>
24. ND, Lias F, Menabo R, Ciman M, Sartyoreli L. Transport functions of carnitine in muscles. J Clin Chem Clin Biochem 1990; 28:303-6.
25. KM, Rowe TC, Yang L et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226:446-68.
<https://doi.org/10.1126/science.6093249>
26. Z, Shenkin A, Bláha V, Sobotka L, Cerman J, Solichová D. Metabolic response to glucose and insulin in weight-stable and weight loosing patients. Clin Biochem Metab 1996; 25:125-30.
